Filing Details

Accession Number:
0001209191-22-020638
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-22 19:28:14
Reporting Period:
2022-03-21
Accepted Time:
2022-03-22 19:28:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1807120 Design Therapeutics Inc. DSGN Pharmaceutical Preparations (2834) 823929248
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1848372 Arsani William C/O Design Therapeutics, Inc.
6005 Hidden Valley Road, Suite 110
Carlsbad CA 92011
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-03-21 25,000 $18.99 2,797,501 No 4 P Indirect By Logos Global Master Fund LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Logos Global Master Fund LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,217,627 Indirect By Logos Opportunities Fund II, L.P.
Common Stock 2,032,501 Indirect By Logos SPV 1 LP
Footnotes
  1. The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  2. Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.